Lupin’s subsidiary receives USFDA approval for generic Avapro Tablets

17 Oct 2012 Evaluate

Lupin’s subsidiary - Lupin Pharmaceuticals Inc. has received final approval for its Irbesartan Tablets 75mg, 150mg and 300mg from the United States Food and Drugs Administration (USFDA) to market a generic version of Sanofi Aventis US, LLC’s (Sanofi Aventis) Avapro Tablets, 75mg, 150mg and 300mg strengths.

Lupin’s Irbesartan Tablets 75mg, 150mg and 300mg are the AB-rated generic equivalent of Sanofi Aventis’s Avapro Tablets. Irbesartan is an angiotensin II receptor antagonist and is indicated for the treatment of Hypertension and Nephropathy in Type 2 Diabetic patients. Avapro Tablets had annual US sales of approximately $400.7 million (IMS MAT June 2012 sales).

Lupin has a vibrant presence in the Indian pharmaceuticals market and has over the past several years made major strides in expanding its therapy portfolio. The company has a robust promotion and distribution setup along with a strong presence in various therapeutic areas, including the fast growing diabetes market.

Lupin Share Price

2079.50 -33.45 (-1.58%)
29-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.50
Dr. Reddys Lab 1268.60
Cipla 1494.40
Zydus Lifesciences 904.00
Lupin 2079.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×